Here is a fat-loss intervention that requires no drug, no gym membership, and no change to your diet. You wear it. That is the entire protocol. And almost no one in clinical practice has heard of it.

It is a weighted vest. Not for cardio, not for step count, not for bone density. The idea is stranger and more interesting than any of those. It rests on a proposed homeostatic system that most physicians were never taught, because it was only described in the last several years. Its discoverers call it the gravitostat.

For 30 years, the story of body-weight regulation had one hero: leptin. Fat cells make leptin, the brain reads it, appetite and metabolism adjust. Elegant. The problem is that in most people with obesity, leptin is already high, and giving more of it does very little. Something else is defending fat mass.

In 2018, a Gothenburg group led by John-Olov Jansson and Claes Ohlsson proposed a second system. They implanted weighted capsules into rodents. The animals compensated by eating less and losing fat, then drifted back toward baseline once the load came off. Critically, the effect held in leptin-deficient mice. Two independent feedback loops for fat mass, not one. They named the load-sensing system the gravitostat, and proposed that osteocytes, the sensor cells buried inside weight-bearing bone, register how heavy the body is.

That last sentence is the one to hold onto. It will matter more than anything else in this article.

In 2020, the same team ran the first human test in EClinicalMedicine. They recruited 69 adults with class 1 obesity (BMI 30 to 35) and randomized them to wear a vest 8 hours a day for 3 weeks. One group carried a heavy vest, weighted to 11% of body weight. The control group wore an identical-looking vest weighted to 1%. Otherwise everyone lived normally. No diet. No prescribed exercise.

The heavy-vest group lost more. Body weight fell 1.4% more than control, with a p-value of 0.000015. Fat mass dropped 4.0% relative to control. Fat-free mass did not budge. In 3 weeks, wearing weight, the body selectively shed fat and spared muscle.

The proof of concept used bioimpedance, a blunt instrument. So in 2025 the same group published something far more rigorous in BMC Medicine: the ATLAS trial. Same design, 11% vest versus 1% vest, 8 hours a day, extended to 5 weeks in 58 adults with class 1 obesity. This time they brought the gold-standard toolkit. DXA for body composition. CT for visceral, subcutaneous, and liver fat. Doubly labelled water to measure total energy expenditure in free-living people. Accelerometers on every participant.

Read the last line again. The scale did not move. Fat went down, muscle went up, and the two changes roughly cancelled on the readout patients actually care about. Had these participants judged the experiment by their bathroom scale, they would have concluded nothing happened. Their bodies had quietly recomposed underneath a flat number.

Then it gets genuinely odd. The fat loss was regional. It appeared in the legs and trunk, the parts of the body actually bearing the load, and not in the arms, which carried nothing. And the mechanism everyone expected turned out to be missing.

What is the signal, then? Honestly, we do not fully know. What we can say is what it is not. Not a calorie-burn story, because expenditure did not rise. Not an appetite story you can see in these data, because intake did not fall. Not simple exercise, because the group that lost fat moved less. A separate human imaging study from the same group found that loading increases glucose uptake in the muscles, bones, and bone marrow of the lower limbs. Whatever the vest is doing, it is doing part of it right where the weight sits.

Everything above is interesting physiology with a modest effect size. About 1 kg of fat over a month is not going to compete with an incretin. If the gravitostat were only a weak fat-loss tool, it would be a curiosity.

But a separate research program, led by Kristen Beavers at Wake Forest, asked a different and much better question. Not "can a vest make you lose weight." Instead: what happens when someone loses weight the normal way, and the body decides to take it back?

Recall the core claim. The gravitostat senses load. When you lose 10 kg, you have unloaded your skeleton by 10 kg, and the sensor should read that as a deficit and start pushing weight back on. So what if you kept the load on artificially, with a vest, while the fat came off? You would be lying to the sensor. In theory, the regain machinery never switches on.

Beavers' group tested exactly that. Older adults with obesity did a 6-month calorie-restriction program, randomized to wear a weighted vest up to 10 hours a day or not. Both groups lost roughly the same weight, about 11 kg. Then everyone went home and was left alone for 18 months.

Look at that bottom row. Metabolic adaptation, the slowing of resting metabolism that follows weight loss and helps drive regain, is one of the most reliably documented phenomena in obesity medicine. It is the reason "just keep doing what you did" stops working. In the group without a vest, resting metabolic rate fell by about 238 kcal per day, right on schedule.

In the vest group it fell by 16. Essentially not at all. The adaptation was abolished. And 18 months later, that group had kept half their weight off while the control group had every kilogram back.

Now, the sober part. This was 18 people. Nine per arm. A convenience sample returning for a voluntary follow-up. The between-group weight difference at 24 months did not reach statistical significance (p = 0.10). This is a hypothesis-generating pilot and its authors say so plainly. You should not change practice on it.

But consider what it is proposing. Not a better way to lose weight. A way to stop the body from taking it back. That is the single hardest problem in this field, and nothing in our toolkit solves it except staying on the drug forever.

I am not going to sell you the good trials and hide the bad one. The largest weighted-vest study ever run is a negative trial, and you should know about it.

INVEST in Bone Health, published in JAMA Network Open in 2025, randomized 150 older adults with obesity to 12 months of weight loss alone, weight loss plus a weighted vest worn about 7 hours a day, or weight loss plus supervised resistance training. The question was whether replacing the lost weight externally could protect the skeleton, since weight loss reliably costs bone and fractures in older adults are catastrophic.

It did not work. All three groups lost hip bone mineral density at similar rates. Neither the vest nor resistance training rescued it. A well-powered, year-long, properly conducted miss.

Here is the nuance that matters, and it is a real one rather than an excuse. INVEST tested bone density, not fat mass or metabolic rate. The gravitostat hypothesis says bone acts as a sensor of load that signals the brain. It does not require that bone density itself improve. A thermostat can read the room temperature accurately without the thermostat getting warmer. So INVEST does not refute the gravitostat. What it does do is close off the most intuitive clinical application, and it is a warning against assuming this vest is good for everything.

None of that makes it fake. It makes it early. A reproducible, randomized fat-loss signal that does not run through appetite or measured energy expenditure is worth attention precisely because it does not fit the model we teach.

I am not writing a prescription off an 18-person pilot. But the intervention is cheap, non-pharmacological, and the main downside is a sore back, so the risk-benefit for a healthy, mobile adult is not exotic. If you want to experiment, the trials point to the sensible version. A load in the neighborhood of 10% of body weight. Worn while upright for several hours a day, since a vest does nothing for the gravitostat while you are lying down. Built up gradually rather than strapped on all at once. The people who got hurt got hurt from doing too much too fast.

And watch the right endpoint. If ATLAS generalizes, the scale is the wrong instrument. A tape measure at the waist will tell you far more, because body weight is exactly the number the gravitostat is content to leave alone while it rearranges what sits underneath.

The weighted vest is a mediocre weight-loss drug and possibly a remarkable anti-regain one. Randomized human data say that carrying load makes the body shed fat and build muscle without eating less or moving more, and that keeping the load on during a diet may prevent the metabolic slowdown that reclaims the weight afterward. The effects are small, the trials are small, and the biggest one missed. But the underlying idea, that the skeleton is running a fat thermostat nobody knew about, is the most genuinely novel thing to enter obesity physiology in a decade. It deserves a real trial. Somebody should run it.

REFERENCES

1. Ohlsson C, Gidestrand E, Bellman J, Larsson C, Palsdottir V, Hägg D, Jansson PA, Jansson JO. Increased weight loading reduces body weight and body fat in obese subjects: a proof of concept randomized clinical trial. EClinicalMedicine. 2020;22:100338. doi:10.1016/j.eclinm.2020.100338. (NCT03672903)

2. Bellman J, Westerterp K, Wouters L, Johannesson M, Lundqvist N, Kullberg J, et al. Increased weight-load improves body composition by reducing fat mass and waist circumference, and by increasing lean mass in participants with obesity: a single-centre randomised controlled trial. BMC Med. 2025;23:317. doi:10.1186/s12916-025-04143-6. (ATLAS; NCT04697238)

3. DeLong C, Nicklas BJ, Beavers DP, Fanning J, Beavers KM. Does weighted vest use during weight loss influence long-term weight loss maintenance? A pilot study in older adults living with obesity and osteoarthritis. Int J Obes (Lond). 2025;49(8):1662–1665. doi:10.1038/s41366-025-01795-5.

4. Beavers KM, Lynch SD, Fanning J, Howard M, Lawrence E, Lenchik L, et al. Weighted vest use or resistance exercise to offset weight loss-associated bone loss in older adults: a randomized clinical trial. JAMA Netw Open. 2025;8(6):e2516772. doi:10.1001/jamanetworkopen.2025.16772. (INVEST; NCT04076618)

5. Jansson JO, Palsdottir V, Hägg DA, Schéle E, Dickson SL, Anesten F, et al. Body weight homeostat that regulates fat mass independently of leptin in rats and mice. Proc Natl Acad Sci U S A. 2018;115(2):427–432. doi:10.1073/pnas.1715687114.

6. Ohlsson C, Hägg DA, Hammarhjelm F, Dalmau Gasull A, Bellman J, Windahl SH, et al. The gravitostat regulates fat mass in obese male mice while leptin regulates fat mass in lean male mice. Endocrinology. 2018;159(7):2676–2682. doi:10.1210/en.2018-00307.

7. Bellman J, Sjöros T, Hägg D, Atencio Herre E, Hieta J, Eskola O, et al. Loading enhances glucose uptake in muscles, bones, and bone marrow of lower extremities in humans. J Clin Endocrinol Metab. 2024;109(12):3126–3136. doi:10.1210/clinem/dgae344.

8. Zlatkovic J, Dalmau Gasull A, Hägg D, Font-Gironès F, Bellman J, Meister B, et al. Reduction of body weight by increased loading is associated with activation of norepinephrine neurones in the medial nucleus of the solitary tract. J Neuroendocrinol. 2023;35(12):e13352. doi:10.1111/jne.13352.

9. Schwartz A, Doucet E. Relative changes in resting energy expenditure during weight loss: a systematic review. Obes Rev. 2010;11(7):531–547.